Vimseltinib is under clinical development by Deciphera Pharmaceuticals and currently in Pre-Registration for Tenosynovial Giant Cell Tumor. According to GlobalData, Pre-Registration drugs for Tenosynovial Giant Cell Tumor have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Vimseltinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vimseltinib overview
Vimseltinib (DCC-3014) is under development for the treatment of advanced malignancies such as solid tumors and tenosynovial giant cell tumor and chronic graft versus host disease. It is administered orally. The drug candidate acts by targeting the FMS kinase (also known as CSF1R). It is developed based on kinase inhibitor technology. It was also under development for the treatment of glioma, renal cell carcinoma and osteolytic cancer.
It was also under development for the treatment of acute myeloid leukemia (AML), colorectal cancer, bone metastasis, prostate cancer, myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL).
Deciphera Pharmaceuticals overview
Deciphera Pharmaceuticals is a research and development company that develops, designs and commercializes kinase-inhibiting drugs. The company provides a clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses a proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals pipeline products include ripretinib, vimseltinib, DCC-3009, DCC-3116 and DCC-3084 treat renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, Crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Vimseltinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
